COMPOSITION FOR OBESITY TREATMENT COMPRISING LIQUID-PHASE PLASMA

• US 20190313520A1
• Filed: 09/19/2017
• Published: 10/10/2019
• Est. Priority Date: 09/22/2016
• Status: Active Grant

• Current Assignee: Ajou University Industry
• Original Assignee: Industry-Academic Cooperation Foundation Yonsei University
• Inventors: KIM, Chul Ho, KANG, Sung Un
• Granted Patent: US 10,537,014 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/2004 Excipients; Inactive ingredients
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: H05H 1/24 Generating plasma nuclear fusion reactors G21B1/00; gas-filled discharge reactors H01J37/32
• CPC Class Codes: H05H 2245/30 Medical applications

Abstract

Provided is a composition for obesity treatment comprising a liquid-phase plasma. More particularly, provided is a method for producing a liquid-phase plasma for inhibiting adipocyte differentiation or proliferation, a pharmaceutical composition for obesity prevention or treatment using a liquid-phase plasma produced according to the method, and a method for obesity prevention or treatment using the liquid-phase plasma.

Claims

1. A method of producing liquid type plasma for inhibiting adipogenic differentiation, the method comprising:

(a) filling a plasma generator with a carrier gas;

(b) supplying a voltage of 1 kV to 20 kV and a frequency of 10 kHz to 30 kHz to the plasma generator to generate plasma; and

(c) treating a liquid material with the generated plasma.

2. The method of claim 1, wherein, in process (a), the carrier gas comprises any one or more selected from the group consisting of nitrogen, helium, argon, and oxygen.

3. The method of claim 2, wherein the carrier gas is a mixture of helium and oxygen in a volume (vol %) ratio of 20:

80.

4. The method of claim 1, wherein the treating of process (c) is performed at a distance of 0.1 cm to 15 cm from a surface of the liquid material for 1 minute per 1 ml.

5. The method of claim 1, wherein the liquid material of process (c) is water, saline, a buffer, or a medium.

6. A composition for inhibiting adipogenic differentiation, the composition comprising liquid type plasma produced using the method of claim 1.

7. A pharmaceutical composition for preventing or treating obesity, the pharmaceutical composition comprising the composition of claim 6 as an active ingredient.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is in the form of an oral preparation, a parenteral preparation, or a local preparation.

9. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is used alone or in combination with surgery, radiotherapy, hormone treatment, chemotherapy, and methods using a biological response modifier.

10. A method of preventing or treating obesity, the method comprising administering the pharmaceutical composition of claim 7 to an individual.

11. (canceled)